Chronic Hepatitis B virus infection is a common cause of severe liver disease and liver cancer.  Currently available treatment options cannot fully suppress viral replication in the majority of patients and only show very low cure rates.  Consequently, the identification of antivirals with a new mechanism of action should allow for the intensification of HBV suppression towards fully blocking HBV production in the liver and thus improve treatment outcomes toward the identification of a cure. The HBV core capsid protein has multiple essential functions in the HBV life cycle to enable chronic HBV infection.  As such, it is an important target for antiviral drug development.  NVR 3-778 is a first-in-class sulfonyl carboxamide-based HBV capsid assembly modulator (CAM) that has demonstrated proof of mechanism in a Phase I clinical trial.  This presentation will describe the identification and hit to lead SAR of a completely novel series of pyrazolo piperidine HBV capsid assembly modulators. <br/>

Identification of a new class of HBV capsid assembly modulator

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.